Nuclera, a Cambridge, UK- and Boston, Massachusetts-based biotech company developing benchtop protein printing technologies, raised $42.5 million in the first close of its Series B financing.
Backers included M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh.
The company intends to use the funds to accelerate the development and commercialization of its eProtein™ desktop bioprinter.
Led by Michael Chen, Co-founder and CEO, Nuclera is a pioneer in making biology accessible through its eProtein™ desktop bioprinting technology. With desktop bioprinting, researchers and scientists take control of biology through streamlined access to a next-day supply of proteins. The technology has gained traction with customers in the pharmaceutical, biotech, agribiotech, and synthetic biology industries, which are already working with the company to accelerate their innovation pipelines.
In May 2021, Nuclera acquired the digital microfluidic operations at E Ink in Boston, Massachusetts along with a UK Future Fund investment led by E Ink. The company now has 70 employees and is headquartered in Cambridge, UK and Boston, Massachusetts.
FinSMEs
02/02/2022